The present invention provides a compound represented by the formula
wherein A represents (1) a bond, (2) a group represented by the formula -CRa=CRb- (Ra and Rb each represent a hydrogen atom or C1-6 alkyl) and the like; R1 represents (1) cyano or (2) an optionally esterified or amidated carboxyl group; R2 represents
(1) a hydrogen atom, (2) an optionally substituted hydroxy group,
(3) an optionally substituted amino group and the like; R3 and R4 each represent a hydrogen atom and the like; R5 represents a hydrogen atom and the like; R6 represents an optionally substituted hydroxy group and the like; R7and R8 each represent an optionally substituted hydrocarbon group and the like; R9 and R10 each represent (1) a hydrogen atom and the like; Y represents an optionally substituted methylene group; and n represents 0 or 1, or a salt thereof, which has an excellent phosphodiesterase IV inhibiting action.
.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
[EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER PAR DES AMIDES D'ACIDE ARYL ALCANOIQUE
申请人:ELAN PHARM INC
公开号:WO2003103653A1
公开(公告)日:2003-12-18
Disclosed are methods for treating Alzheimer’s disease, and other diseases,
and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of
A beta peptide in a mammal, by use of compounds of formula 1 (1) wherein the variables
R1-R8 and X are defined herein.
[EN] INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS<br/>[FR] NOUVEAUX COMPOSÉS
申请人:GLAXO GROUP LTD
公开号:WO2009050243A1
公开(公告)日:2009-04-23
The present invention provides compounds of formula (I), a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates, and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation and/or allergic conditions.
Imidazol-4-one or imidazole-4-thione compounds of formula (I):
wherein X, R
1
, R
2
, R
3
, R
4
, R
5
, and R
6
are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.